Hiroki Hara Selected Research

Fluorouracil (Carac)

12/2022	First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048.
1/2022	Multicenter phase II study of trifluridine/tipiracil for esophageal squamous carcinoma refractory/intolerant to 5-fluorouracil, platinum compounds, and taxanes: the ECTAS study.
11/2021	Clinical implications of using both fluoropyrimidine and paclitaxel in patients with severe peritoneal metastasis of gastric cancer: A post hoc study of JCOG1108/WJOG7312G.
2/2021	A management of neutropenia using granulocyte colony stimulating factor support for chemotherapy consisted of docetaxel, cisplatin and 5-fluorouracil in patients with oesophageal squamous cell carcinoma.
1/2021	Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
4/2020	TENERGY: multicenter phase II study of Atezolizumab monotherapy following definitive Chemoradiotherapy with 5-FU plus Cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinoma.
2/2020	A 3-Year Overall Survival Update From a Phase 2 Study of Chemoselection With DCF and Subsequent Conversion Surgery for Locally Advanced Unresectable Esophageal Cancer.
1/2020	Randomized phase II/III study of 5-fluorouracil/l-leucovorin versus 5-fluorouracil/l-leucovorin plus paclitaxel administered to patients with severe peritoneal metastases of gastric cancer (JCOG1108/WJOG7312G).
1/2020	Chemoradiotherapy with FOLFOX for esophageal squamous cell cancer with synchronous rectal cancer: Four case reports and a literature review.
12/2019	Phase III study of tri-modality combination therapy with induction docetaxel plus cisplatin and 5-fluorouracil versus definitive chemoradiotherapy for locally advanced unresectable squamous-cell carcinoma of the thoracic esophagus (JCOG1510: TRIANgLE).

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hiroki Hara Research Topics

Disease

45	Neoplasms (Cancer) 02/2024 - 09/2008
29	Stomach Neoplasms (Stomach Cancer) 01/2024 - 09/2008
24	Colorectal Neoplasms (Colorectal Cancer) 02/2024 - 12/2014
23	Esophageal Squamous Cell Carcinoma 05/2024 - 11/2013
12	Disease Progression 01/2024 - 02/2014
10	Esophageal Neoplasms (Esophageal Cancer) 04/2024 - 01/2019
10	Neoplasm Metastasis (Metastasis) 09/2023 - 11/2015
9	Adenocarcinoma 08/2023 - 01/2017
6	Neutropenia 01/2023 - 11/2013
5	Carcinoma (Carcinomatosis) 11/2023 - 07/2016
5	Microsatellite Instability 01/2023 - 12/2014
5	Squamous Cell Carcinoma (Epidermoid Carcinoma) 10/2022 - 11/2016
5	Infections 02/2021 - 06/2002
4	Squamous Cell Carcinoma of Head and Neck 09/2023 - 01/2022
3	Pneumonia (Pneumonitis) 12/2022 - 10/2011
3	Anorexia 10/2022 - 11/2013
3	Pancreatic Neoplasms (Pancreatic Cancer) 02/2021 - 01/2016
3	Interstitial Lung Diseases (Interstitial Lung Disease) 10/2018 - 02/2014
2	Drug-Related Side Effects and Adverse Reactions 02/2024 - 01/2017
2	Exanthema (Rash) 10/2022 - 01/2020
2	Hyponatremia 10/2022 - 01/2019
2	Head and Neck Neoplasms (Head and Neck Cancer) 01/2022 - 01/2022
2	Febrile Neutropenia 02/2021 - 01/2017
2	Leukopenia 01/2021 - 01/2019
2	Ascites 01/2020 - 04/2018
1	Esophageal Stenosis (Esophageal Stricture) 05/2023
1	Cholangiocarcinoma 01/2023
1	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 01/2023
1	Biliary Tract Neoplasms (Biliary Tract Cancer) 01/2022

Drug/Important Bio-Agent (IBA)

16	Cisplatin (Platino)FDA LinkGeneric 01/2022 - 11/2013
15	Fluorouracil (Carac)FDA LinkGeneric 12/2022 - 11/2013
14	NivolumabIBA 02/2024 - 01/2017
12	pembrolizumabIBA 04/2024 - 01/2019
11	PlatinumIBA 04/2024 - 08/2013
11	Docetaxel (Taxotere)FDA Link 01/2024 - 11/2013
8	Paclitaxel (Taxol)FDA LinkGeneric 01/2024 - 01/2017
8	Cetuximab (Erbitux)FDA Link 08/2023 - 01/2018
7	Irinotecan (Camptosar)FDA LinkGeneric 08/2023 - 01/2020
6	trifluridine tipiracil drug combinationIBA 08/2023 - 11/2020
5	Immune Checkpoint InhibitorsIBA 05/2024 - 01/2020
5	Biomarkers (Surrogate Marker)IBA 01/2023 - 12/2014
5	Leucovorin (Folinic Acid)FDA Link 11/2021 - 04/2018
5	Oxaliplatin (Eloxatin)FDA LinkGeneric 08/2021 - 01/2020
4	taxaneIBA 04/2024 - 01/2017
4	regorafenibIBA 02/2024 - 01/2020
4	B7-H1 AntigenIBA 09/2023 - 01/2021
4	human ERBB2 proteinIBA 06/2022 - 08/2017
4	Trastuzumab (Herceptin)FDA Link 01/2022 - 08/2013
3	RamucirumabIBA 08/2023 - 07/2020
3	Taxoids (Taxanes)IBA 06/2023 - 03/2021
3	ErbB Receptors (EGF Receptor)IBA 01/2022 - 08/2013
3	Monoclonal AntibodiesIBA 01/2022 - 01/2019
3	130-nm albumin-bound paclitaxelIBA 08/2021 - 01/2017
3	Gemcitabine FDA Link 02/2021 - 01/2016
3	Alanine Transaminase (SGPT)IBA 01/2020 - 10/2011
2	tislelizumabIBA 01/2024 - 10/2022
2	Bevacizumab (Avastin)FDA Link 01/2023 - 01/2022
2	Programmed Cell Death 1 ReceptorIBA 10/2022 - 01/2021
2	Proteins (Proteins, Gene)FDA Link 06/2022 - 01/2021
2	AntibodiesIBA 01/2022 - 06/2002
2	Platinum Compounds (Compounds, Platinum)IBA 01/2022 - 07/2020
2	Circulating Tumor DNAIBA 01/2022 - 10/2021
2	HLA Antigens (Human Leukocyte Antigens)IBA 05/2020 - 04/2020
2	Everolimus FDA Link 01/2020 - 02/2014
2	CreatinineIBA 10/2018 - 01/2017
1	3-amino-1-methyl-3-(4-(3-phenyl-5H- imidazo(1,2- c)pyrido(3,4- e)(1,3)oxazin- 2- yl)phenyl)cyclobutanolIBA 02/2024
1	1-(2-(dodecyloxy)ethyl)pyrrolidine hydrochloride (DEP)IBA 02/2024
1	TAS-116IBA 02/2024
1	RNA (Ribonucleic Acid)IBA 02/2024
1	eribulin FDA Link 01/2024
1	Tumor Biomarkers (Tumor Markers)IBA 01/2024
1	encorafenibIBA 08/2023
1	binimetinibIBA 08/2023
1	pemigatinibIBA 01/2023
1	Trifluridine (Viroptic)FDA LinkGeneric 01/2023
1	NVP-BKM120IBA 10/2022
1	Notch ReceptorsIBA 10/2022
1	Type 2 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 2)IBA 06/2022
1	ParaffinIBA 01/2022
1	Hematoxylin (Haematoxylon)IBA 01/2022
1	durvalumabIBA 01/2022
1	CTLA-4 AntigenIBA 01/2022
1	Formaldehyde (Formol)FDA Link 01/2022
1	tremelimumabIBA 01/2022
1	lenvatinibIBA 01/2022
1	Eosine Yellowish-(YS) (Eosin)IBA 01/2022
1	pevonedistatIBA 08/2021
1	Capecitabine (Xeloda)FDA Link 08/2021

Therapy/Procedure

51	Drug Therapy (Chemotherapy) 04/2024 - 09/2008
24	Therapeutics 01/2024 - 02/2014
9	Chemoradiotherapy 11/2022 - 07/2016
6	Induction Chemotherapy 02/2021 - 07/2016
4	Adjuvant Chemotherapy 01/2019 - 12/2014
3	Neoadjuvant Therapy 05/2024 - 09/2008
3	Immunotherapy 02/2024 - 04/2020
3	Radiotherapy 01/2019 - 11/2015
2	Salvage Therapy 11/2022 - 10/2020
1	Endoscopes 05/2023
1	Molecular Targeted Therapy 01/2022
1	Precision Medicine 01/2022